Education
About Us
Working with TipRanks
Follow Us
Co-Diagnostics Inc (CODX)
NASDAQ:CODX
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.62Last Year’s EPS
-0.25Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -36.11%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
Co-Diagnostics is making significant strides in developing and preparing its Co-Dx PCR platform and related diagnostic tests for market entry. However, the company faces financial challenges, including a significant decrease in revenue and ongoing net losses. Plans for clinical evaluations and regulatory submissions are underway, supported by strong partnerships and grants, but depend on external factors like disease prevalence.Company Guidance
During the first quarter of 2025, Co-Diagnostics made significant strides in advancing its Co-Dx PCR platform and associated test pipeline, including preparations for clinical evaluations of tests for tuberculosis (TB), COVID-19, a 4-plex respiratory panel, and an 8-plex HPV panel. The company is gearing up to submit an updated version of its COVID-19 test for FDA 510(k) clearance, following extensive verification testing and design improvements. Co-Diagnostics plans to initiate clinical evaluations for these tests in India and South Africa later in 2025, leveraging its joint venture CoSara Diagnostics for regulatory and commercial infrastructure. Financially, Co-Diagnostics reported a first-quarter revenue decrease to $0.1 million from $0.5 million in the prior year, with total operating expenses reduced to $8.6 million and a net loss of $7.5 million. The company ended the quarter with $21.5 million in cash and equivalents, focusing on maintaining a healthy balance sheet and progressing its development pipeline.Advancement of Co-Dx PCR Platform
Significant progress on Co-Dx PCR platform, with clinical evaluations planned for TB, COVID-19, respiratory, and HPV tests. Support from organizations like Bill & Melinda Gates Foundation and NIH's RADx Tech program.
TB Test Development and Market Potential
Successful preliminary studies for TB test and preparations for evaluations in India and South Africa, targeting high-demand markets with existing infrastructure in place.
4-Plex Respiratory Panel and HPV Panel Progress
Development supported by NIH's RADx Tech and Bill & Melinda Gates Foundation grants, targeting critical health needs with planned clinical evaluations in 2025.
Engagement and Awareness Initiatives
Participation in events like International HPV Awareness Day, enhancing visibility and stakeholder engagement for the Co-Dx PCR platform.
CODX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CODX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $0.36 | $0.34 | -5.56% |
Mar 27, 2025 | $0.39 | $0.32 | -17.95% |
Nov 07, 2024 | $1.18 | $1.14 | -3.39% |
Aug 08, 2024 | $1.02 | $1.12 | +9.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Co-Diagnostics Inc (CODX) report earnings?
Co-Diagnostics Inc (CODX) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Co-Diagnostics Inc (CODX) earnings time?
Co-Diagnostics Inc (CODX) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CODX EPS forecast?
CODX EPS forecast for the fiscal quarter 2025 (Q2) is -0.62.